Homepage > Company > Media > Pharma News > 2020 > Supernus drug meets main goal of study in adults with ADHD

Supernus drug meets main goal of study in adults with ADHD

(Reuters) - Supernus Pharmaceuticals Inc said on Tuesday its experimental drug for attention deficit hyperactivity disorder (ADHD) met the main goal of a late-stage study in adults.

The drug, SPN-812, was better able to improve symptoms of ADHD compared with a placebo, the company said.

SPN-812 is currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of ADHD in children 6 to 17 years of age.

Last month, the FDA declined to approve the drug for use in children, citing an issue related to the company’s laboratory that conducts analytical testing, which recently moved to a new location.

Supernus on Tuesday said it would meet the FDA in January to discuss the application.

If approved in children, the company said it would file an application with the agency for marketing SPN-812 to adults in the second half of next year.

The adult ADHD patient population represents about half of the total ADHD market in the United States, the company said.

DECEMBER 23, 2020

https://www.reuters.com/

Read also

Merck gains rights to LaNova’s PD-1/VEGF bispecific antibody in deal worth over $3.2bn

Merck & Co – known as MSD outside the US and Canada – has entered into an exclusive global licensing agreement worth over $3.2bn to advance LaNova Medicines’ investigational PD-1/VEGF bispecific...

Rectify Pharma Presents Preclinical Data Supporting Development of Lead Candidate RTY-694 at The Liver Meeting® 2024

Rectify Pharmaceuticals, Inc., a biotechnology company developing positive functional modulators (PFMs), small molecule therapeutics that restore and enhance membrane protein function, today ...

Ideaya hires Gilead leader to head up commercialization push

Ideaya Biosciences has made a key hire in anticipation of the launch of its first drug, securing the services of an executive who played a role in the commercialization of Trodelvy and Opdivo.

Silo Pharma discloses ‘promising results’ from preclinical study on SPC-15

Silo Pharma announced promising results from a preclinical study on SPC-15. This new formulation, which targets both the serotonin 5-HT4 receptor, 5-HT4R, and the NMDA receptor, NMDAR, has shown poten...